Reversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapy

dc.contributor.authorMiró i Andreu, Òscar
dc.contributor.authorLópez Moreno, Sònia
dc.contributor.authorMartínez, Esteban
dc.contributor.authorRodríguez Santiago, Benjamín
dc.contributor.authorBlanco, José L.
dc.contributor.authorMilinkovic, Ana
dc.contributor.authorMiró Meda, José M. (José María), 1956-
dc.contributor.authorNunes Martínez, Virginia
dc.contributor.authorCasademont i Pou, Jordi
dc.contributor.authorGatell, José M.
dc.contributor.authorCardellach, Francesc
dc.date.accessioned2013-05-03T10:53:02Z
dc.date.available2013-05-03T10:53:02Z
dc.date.issued2003-11
dc.date.updated2013-05-03T10:53:02Z
dc.description.abstractDirect evidence confirming the hypothesis that a dysfunction of the mitochondrial respiratory chain (MRC) underlies the pathogenesis of hyperlactatemia associated with highly active antiretroviral therapy (HAART) is scarce. We studied mitochondrial DNA (mtDNA) content and MRC function in the skeletal muscle of an HIV-infected patient during an episode of symptomatic hyperlactatemia. Skeletal muscle biopsy was performed during the episode when the patient was symptomatic and 3 months later when the patient was clinically recovered. Assessment of mitochondria was performed using histological, polarographic, spectrophotometrical, and Southern blot and real time PCR DNA quantification methods. The histological study disclosed extensive mitochondrial impairment in the form of ragged-red fibers or equivalents on oxidative reactions. These findings were associated with an increase in mitochondrial content and a decrease in both mitochondrial respiratory capacity and MRC enzyme activities. Mitochondrial DNA content declined to 53% of control values. Mitochondrial abnormalities had almost disappeared later when the patient became asymptomatic. Our findings support the hypothesis that MRC dysfunction stands at the basis of HAART-related hyperlactatemia.
dc.format.extent6 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec513587
dc.identifier.issn0889-2229
dc.identifier.pmid14678610
dc.identifier.urihttps://hdl.handle.net/2445/41682
dc.language.isoeng
dc.publisherMary Ann Liebert, Inc.
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1089/088922203322588387
dc.relation.ispartofAids Research and Human Retroviruses, 2003, vol. 19, num. 11, p. 1027-1032
dc.relation.urihttp://dx.doi.org/10.1089/088922203322588387
dc.rights(c) Mary Ann Liebert, Inc., 2003
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationAntiretrovirals
dc.subject.classificationADN mitocondrial
dc.subject.otherAntiretroviral agents
dc.subject.otherMitochondrial DNA
dc.titleReversible mitochondrial respiratory chain impairment during symptomatic hyperlactatemia associated with antiretroviral therapyeng
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
513587.pdf
Mida:
361.39 KB
Format:
Adobe Portable Document Format